

Cost Comparison Review: Semaglutide vs Tirzepatide in India (August 2025)

Gyayak Jain*, Meetakshi Saraf

Abstract

This review analyzes the current pricing of **semaglutide (Wegovy)** and **tirzepatide (Mounjaro)** in India as of August 2025, explores the impact of generics, and discusses trends affecting accessibility for obesity and diabetes management.

Introduction

Semaglutide and tirzepatide are two leading GLP-1 receptor agonists with proven effectiveness in the management of obesity and type 2 diabetes. While global prices remain high, India has experienced significant reductions, driven by local manufacturing and regulatory changes that encourage generic competition.^{[1][2]}

Current Price Overview (INR)

- Semaglutide (Wegovy):** ₹17,345–₹26,015/month, administered as a weekly pen.^{[2][3][1]}
- Tirzepatide (Mounjaro):** ₹14,000–₹17,500/month, available in weekly vials (2.5 mg/5 mg) and soon in Kwik Pen form for easier dosing.^{[4][1][2]}
- Cost comparison:** Mounjaro is slightly less expensive than Wegovy at comparable dosing regimens.

Table: Comparative Pricing

Drug	Monthly Cost (INR)	Expected Generic Price (INR, 2026+)
Semaglutide	₹17,345–₹26,015 ^{[1][2][3][5]}	₹3,000–₹6,000 ^{[2][6]}
Tirzepatide	₹14,000–₹17,500 ^{[4][2][1]}	₹3,000–₹7,000 (projected) ^{[2][6]}

Market Dynamics and Generic Impact

The Indian obesity drug market has grown substantially, with current annual revenue expanding from ₹138 crore in 2021 to ₹628 crore in 2025. Tirzepatide earned ₹50 crore within 90 days of launch, demonstrating strong market uptake. Market share is dominated by semaglutide (66%) and tirzepatide (8%), accounting for nearly three-fourths of total value. Experts project that once generics enter by mid-2026, prices for both drugs could drop 80–90%, dramatically improving affordability and broadening patient access.^{[7][6][1][2]}

Future Price Trends

Following patent expiry and regulatory approval, Indian manufacturers are poised to launch generic semaglutide and tirzepatide in 2026. Analysts estimate post-launch retail prices as low as ₹3,000–₹7,000 per month, a major reduction from current branded costs. This price transformation is expected to reshape obesity and diabetes care, bringing innovative medicines to millions more patients across India.^{[6][1][2]}

Conclusion

As of August 2025, **tirzepatide is slightly less expensive than semaglutide for most patients in India**, with both medications offering substantial benefits for weight loss and glycemic control. The impending entry of generics by mid-2026 promises to lower out-of-pocket costs to a fraction of current prices, significantly expanding therapeutic options and improving health outcomes for India's population.^{[8][1][2][7][4]}

REFERENCES

1. <https://www.drrajatgoel.com/mounjaro-vs-wegovy-in-india-price-and-weight-loss-effectiveness/>
2. <https://economictimes.com/industry/healthcare/biotech/healthcare/indian-generics-wave-next-year-set-to-sink-obesity-drug-price/articleshow/123127121.cms>
3. <https://www.drrajatgoel.com/wegovy-cost-in-india/>
4. <https://www.drrajatgoel.com/mounjaro-cost-in-india/>
5. <https://www.linkedin.com/pulse/semaglutide-india-300-million-opportunity-reshaping-chronic-yadav-vhv3c>
6. <https://www.indiatoday.in/health/story/indias-weight-loss-revolution-from-rs-30000-to-rs-3000-the-game-is-changing-but-whats-the-catch-2770170-2025-08-12>
7. <https://medicaldialogues.in/news/industry/pharma/tirzepatide-shakes-up-obesity-market-as-mounjaro-records-rs-390-mn-sales-in-june-151517>
8. <https://www.docgenie.in/blogs/best-weight-loss-medications-in-india/>
9. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12151102/>
10. <https://www.tctmd.com/news/newer-weight-loss-drugs-not-cost-effective-current-prices>
11. <https://www.kauveryhospital.com/blog/family-and-general-medicine/india-approves-tirzepatide-a-diabetes-and-weight-loss-drug/>